Inhibitor Therapeutics, Inc. (INTI)
OQB · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.
Peers in Healthcare
Inhibitor Therapeutics, Inc. has no peer companies in this window.
Recent press releases
April 2026
Inhibitor Therapeutics, Inc. — 8-K Filing
# 🧾 What This Document Is This is a **Form 8-K filing**, specifically an "Exhibit 99.1" which is a **press release** the company wants to officially share with investors. It’s not a dry financial report, but an important update on their main drug development program. Companies use these to announce
SEC filings
All filings →Insider trades
All insider trades →Inhibitor Therapeutics, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Inhibitor Therapeutics, Inc. in this window.